Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mo | AbbVie flashes eye-opening results for Rinvoq in alopecia areata | ||
Mo | Incyte's new CEO pledges 'fresh look' at business, outlines dealmaking strategy | ||
Mo | Lilly confirms plan to sell NJ plant amid larger US production ramp-up | ||
Sa | Regulatory tracker: AstraZeneca's Imfinzi stomach cancer expansion bid snags FDA priority review | ||
Fr | Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions | ||
Fr | Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia | ||
Fr | Despite ongoing decline, Moderna's Spikevax sales beat expectations in Q2 | ||
Fr | J&J coins the term '3rd opinion,' debuts awareness campaign to empower lung cancer patients | ||
Fr | Merz Aesthetics gives sales and marketing leadership a face-lift | ||
Fr | Alnylam exceeds $50B market cap as Amvuttra heart disease launch wows Wall Street | ||
Do | White House threatens to 'deploy every tool in our arsenal' to implement most-favored-nation drug pricing | ||
Do | Merck will lay off 6,000, reducing workforce by 8% in cost-cutting purge | ||
Do | Sanofi touts tariff resilience for rest of 2025 as CEO admits many unknowns persist | ||
Do | AstraZeneca's Alexion spotlights generalized myasthenia gravis for next entry in awareness-raising film series | ||
Do | HHS will demo drugmakers' 340B rebate model in limited pilot program | ||
Do | AbbVie's rumored $1B pursuit of Gilgamesh could fit into its growing neuroscience portfolio | ||
Do | Biogen raises sales outlook as Leqembi awaits FDA decision on new dosing option | ||
Do | Bristol Myers touts commercial execution, reckons with recent clinical setbacks | ||
Do | Evotec offloads France biosimilars plant to Sandoz for $300M | ||
Do | Moderna, working through operating cost and R&D cuts, to sideline 10% of global workforce by year-end | ||
Do | Vinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst | ||
Do | Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial | ||
Mi | J&J, Legend crunch the multiple myeloma numbers in first Carvykti TV ad | ||
Mi | Celltrion closes in on US plant purchase, dubbing drug substance facility 'fundamental' to tariff mitigation | ||
Mi | FDA taps newly appointed George Tidmarsh as acting CBER leader after Prasad exit |